IS8266A - Breytt mennsk IGF-1R mótefni - Google Patents

Breytt mennsk IGF-1R mótefni

Info

Publication number: IS8266A
Authority: IS; Iceland
Prior art keywords: antibody; modified human; human igf; igf; modified
Prior art date: 2003-08-13

Application number

IS8266A

Other languages

English (en)

Inventor

David Cohen Bruce

Bedian Vahe

Original Assignee

Pfizer Products Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-08-13

Filing date

2006-01-26

Publication date

2006-01-26

2006-01-26 Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.

2006-01-26 Publication of IS8266A publication Critical patent/IS8266A/is

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Transplantation (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Oncology (AREA)
Diabetes (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

IS8266A 2003-08-13 2006-01-26 Breytt mennsk IGF-1R mótefni IS8266A (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US49520003P	2003-08-13	2003-08-13
PCT/IB2004/002555 WO2005016967A2 (en)	2003-08-13	2004-08-03	Modified human igf-1r antibodies

Publications (1)

Publication Number	Publication Date
IS8266A true IS8266A (is)	2006-01-26

Family

ID=34193291

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS8266A IS8266A (is)	2003-08-13	2006-01-26	Breytt mennsk IGF-1R mótefni

Country Status (37)

Country	Link
US (2)	US7371378B2 (is)
EP (1)	EP1656391B1 (is)
JP (1)	JP4638870B2 (is)
KR (1)	KR100825156B1 (is)
CN (1)	CN1835975B (is)
AP (1)	AP2006003510A0 (is)
AR (1)	AR045247A1 (is)
AT (1)	ATE484525T1 (is)
AU (1)	AU2004265152A1 (is)
BR (1)	BRPI0413466A (is)
CA (1)	CA2535071A1 (is)
CL (1)	CL2004002035A1 (is)
CR (1)	CR8233A (is)
DE (1)	DE602004029581D1 (is)
DK (1)	DK1656391T3 (is)
EA (1)	EA200600234A1 (is)
EC (1)	ECSP066359A (is)
ES (1)	ES2351395T3 (is)
GT (1)	GT200400158A (is)
IL (1)	IL173273A (is)
IS (1)	IS8266A (is)
MA (1)	MA27988A1 (is)
MX (1)	MXPA06001634A (is)
NL (1)	NL1026829C2 (is)
NO (1)	NO20060542L (is)
OA (1)	OA13234A (is)
PA (1)	PA8608801A1 (is)
PE (1)	PE20050339A1 (is)
PL (1)	PL1656391T3 (is)
PT (1)	PT1656391E (is)
RS (1)	RS20060099A (is)
TN (1)	TNSN06050A1 (is)
TW (1)	TWI294915B (is)
UA (1)	UA85058C2 (is)
UY (1)	UY28464A1 (is)
WO (1)	WO2005016967A2 (is)
ZA (1)	ZA200601231B (is)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MA26040A1 (fr)	2001-01-05	2004-04-01	Pfizer	Des anticorps pour recepteur i de facteur de croissance insulinique
EP2316921B1 (en)	2002-05-24	2014-05-14	Merck Sharp & Dohme Corp.	Neutralizing human anti-IGFR antibody
JP2007535895A (ja) *	2003-05-01	2007-12-13	イムクローンシステムズインコーポレイティド	ヒトインシュリン様成長因子−１受容体に対する完全ヒト抗体
JP4638870B2 (ja) *	2003-08-13	2011-02-23	ファイザー・プロダクツ・インク	修飾ヒトｉｇｆ−１ｒ抗体
CA2545755A1 (en)	2003-11-12	2005-05-26	Schering Corporation	Plasmid system for multigene expression
PE20050928A1 (es)	2003-11-21	2005-11-08	Schering Corp	Combinaciones terapeuticas de anticuerpo anti-igfr1
MX2007000610A (es)	2004-07-16	2007-03-07	Pfizer Prod Inc	Tratamiento de combinacion para enfermedades malignas no hematologicas usando un anti-cuerpo de receptor de factor i de crecimiento de tipo anti-insulina.
FR2873699B1 (fr) *	2004-07-29	2009-08-21	Pierre Fabre Medicament Sa	Nouveaux anticorps anti igf ir rt leurs utilisations
EP2281841A3 (en)	2004-12-03	2013-10-23	Merck Sharp & Dohme Corp.	Biomarkers for pre-selection of patients for anti-IGF1R therapy
MY146381A (en)	2004-12-22	2012-08-15	Amgen Inc	Compositions and methods relating relating to anti-igf-1 receptor antibodies
GB0500417D0 (en) *	2005-01-10	2005-02-16	Cambridge Antibody Tech	Method of mutagenesis
MX2007012896A (es) *	2005-04-15	2007-12-10	Schering Corp	Metodos y composiciones para tratamiento o prevencion de cancer.
NZ564098A (en) *	2005-06-15	2010-04-30	Schering Corp	Anti-IGF1R antibody formulations
CN101612399B (zh) *	2005-06-17	2013-11-27	英克隆有限责任公司	用作治疗继发性骨肿瘤的抗PDGFRα抗体
FR2888850B1 (fr)	2005-07-22	2013-01-11	Pf Medicament	Nouveaux anticorps anti-igf-ir et leurs applications
CN101484587B (zh) *	2006-02-03	2014-02-12	英克隆有限责任公司	Igf-ir拮抗剂作为辅药用于前列腺癌的治疗
JP2009531371A (ja) *	2006-03-28	2009-09-03	エフ．ホフマン−ラロシュアーゲー	抗ｉｇｆ−１ｒヒト・モノクローナル抗体製剤
US7846724B2 (en)	2006-04-11	2010-12-07	Hoffmann-La Roche Inc.	Method for selecting CHO cell for production of glycosylated antibodies
SI2027470T1 (sl) *	2006-06-02	2013-01-31	Pfizer Products Inc.	Analiza kroĺ˝eäśe tumorske celice
AR064464A1 (es) *	2006-12-22	2009-04-01	Genentech Inc	Anticuerpos anti - receptor del factor de crecimiento insulinico
GB0702888D0 (en) *	2007-02-14	2007-03-28	Glaxo Group Ltd	Novel Antibodies
MX2009009379A (es) *	2007-03-02	2009-09-14	Amgen Inc	Metodos y composiciones para tratar enfermedades tumorales.
AU2012203443B2 (en) *	2007-03-02	2014-03-06	Amgen Inc.	Methods and compositions for treating tumor diseases
BRPI0809112A2 (pt) *	2007-03-22	2014-08-26	Imclone Llc	Formulações estáveis de anticorpos
EP2559771A3 (en)	2007-05-17	2013-06-12	Bristol-Myers Squibb Company	Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
WO2009080278A1 (en)	2007-12-21	2009-07-02	F. Hoffmann-La Roche Ag	Stability testing of antibodies
CA2718918A1 (en) *	2008-03-25	2009-11-26	Schering Corporation	Methods for treating or preventing colorectal cancer
US20110129456A1 (en) *	2008-05-05	2011-06-02	Yaolin Wang	Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer
EP2356154A4 (en) *	2008-11-06	2012-12-19	Alexion Pharma Inc	DEVELOPMENT OF REDUCED IMMUNOGENICITY ANTIBODIES AND METHODS OF MANUFACTURING THEREOF
EP2400985A2 (en)	2009-02-25	2012-01-04	OSI Pharmaceuticals, LLC	Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
EP2236139A1 (en)	2009-03-31	2010-10-06	F. Hoffmann-La Roche AG	Combination therapy of erlotinib with an anti-IGF-1R antibody, which does not inhibit binding of insulin to the insulin receptor
WO2010146059A2 (en)	2009-06-16	2010-12-23	F. Hoffmann-La Roche Ag	Biomarkers for igf-1r inhibitor therapy
TWI513465B (zh)	2009-06-25	2015-12-21	Regeneron Pharma	以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
ES2622366T3 (es)	2009-10-26	2017-07-06	F. Hoffmann-La Roche Ag	Procedimiento para la producción de una inmunoglobulina glucosilada
EP2494070A2 (en)	2009-10-30	2012-09-05	Bristol-Myers Squibb Company	Methods for treating cancer in patients having igf-1r inhibitor resistance
MX2012005345A (es)	2009-12-23	2012-06-08	Esbatech Alcon Biomed Res Unit	Metodo para disminuir inmunogenicidad.
AU2014262201B2 (en) *	2009-12-23	2016-09-15	Novartis Ag	Method for decreasing immunogenicity
US20110200595A1 (en)	2010-02-18	2011-08-18	Roche Glycart	TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
WO2011161119A1 (en)	2010-06-22	2011-12-29	F. Hoffmann-La Roche Ag	Antibodies against insulin-like growth factor i receptor and uses thereof
PE20130643A1 (es)	2010-07-12	2013-06-07	Covx Technologies Ireland Ltd	Conjugados de anticuerpos multifuncionales
JP2014510265A (ja)	2011-02-02	2014-04-24	アムジェンインコーポレイテッド	Ｉｇｆ−１ｒの阻害に関する方法および組成物
WO2012145183A2 (en)	2011-04-19	2012-10-26	Pfizer Inc.	Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
WO2013056069A1 (en)	2011-10-13	2013-04-18	Bristol-Myers Squibb Company	Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
EP3447071A1 (en) *	2012-01-09	2019-02-27	Pfizer Healthcare Ireland	Mutant antibodies and conjugation thereof
EP2631653A1 (en)	2012-02-24	2013-08-28	Charité - Universitätsmedizin Berlin	Identification of modulators of binding properties of antibodies reactive with a member of the insulin receptor family
WO2013152252A1 (en)	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Combination anti-cancer therapy
BR112015010240A2 (pt) *	2012-11-06	2017-08-22	Medimmune Ltd	Terapias de combinação através do uso de mo-léculas de ligação de psl e de pcrv anti-pseudomonas
CN105164157B (zh)	2013-04-29	2024-05-28	豪夫迈·罗氏有限公司	Fc-受体结合的修饰的非对称抗体及使用方法
JP2016528167A (ja)	2013-04-29	2016-09-15	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	ヒトＦｃＲｎ結合改変抗体及び使用方法
CN103319598B (zh) *	2013-05-13	2014-10-22	杭州德同生物技术有限公司	抗胰岛素样生长因子-1受体抗体及其编码基因和应用
WO2015107015A1 (en)	2014-01-15	2015-07-23	F. Hoffmann-La Roche Ag	Fc-region variants with improved protein a-binding
EA039807B1 (ru)	2017-01-06	2022-03-16	ЭйБиЭл БИО ИНК.	Антитело к -синуклеину и его применение
IL272227B2 (en) *	2017-07-27	2025-09-01	iTeos Belgium SA	Anti-tigit antibodies
CN116731173A (zh)	2017-12-14	2023-09-12	Abl生物公司	抗a-syn/igf1r的双特异性抗体及其用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6054561A (en)	1984-02-08	2000-04-25	Chiron Corporation	Antigen-binding sites of antibody molecules specific for cancer antigens
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
US6657103B1 (en)	1990-01-12	2003-12-02	Abgenix, Inc.	Human antibodies derived from immunized xenomice
GB9203459D0 (en)	1992-02-19	1992-04-08	Scotgen Ltd	Antibodies with germ-line variable regions
US5863949A (en)	1995-03-08	1999-01-26	Pfizer Inc	Arylsulfonylamino hydroxamic acid derivatives
MX9708026A (es)	1995-04-20	1997-11-29	Pfizer	Derivados del acido arislfulfonil hidroxamico, composiciones que los contienen y uso de los mismos.
DE69637481T2 (de)	1995-04-27	2009-04-09	Amgen Fremont Inc.	Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
IL118626A0 (en)	1996-06-11	1996-10-16	Xtl Biopharmaceuticals Limited	Anti HBV antibody
IL127567A0 (en)	1996-07-18	1999-10-28	Pfizer	Phosphinate based inhibitors of matrix metalloproteases
JP2000501423A (ja)	1996-08-23	2000-02-08	ファイザーインク．	アリールスルホニルアミノヒドロキサム酸誘導体
CA2332331A1 (en)	1998-05-15	1999-11-25	Francisco Robert	Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
EE05627B1 (et) *	1998-12-23	2013-02-15	Pfizer Inc.	CTLA-4 vastased inimese monoklonaalsed antikehad
EP2319870A3 (en)	1999-03-25	2011-10-26	Abbott GmbH & Co. KG	Human antibodies that bind human IL-12 and methods for producing
ES1042735Y (es)	1999-04-07	2000-02-16	Martinez Fernando Martinez	Vehiculo tripersonal de accionamiento a pedales.
US20030165502A1 (en)	2000-06-13	2003-09-04	City Of Hope	Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
DE10033869C2 (de)	2000-07-12	2003-07-31	Karlsruhe Forschzent	HTS-Kryomagnet und Aufmagnetisierungsverfahren
MA26040A1 (fr)	2001-01-05	2004-04-01	Pfizer	Des anticorps pour recepteur i de facteur de croissance insulinique
WO2002066058A1 (en)	2001-02-19	2002-08-29	Merck Patent Gmbh	Modified anti-egfr antibodies with reduced immunogenicity
EP1798242B1 (fr)	2002-01-18	2013-01-23	Pierre Fabre Medicament	Anticorps anti-IGF-IR et leurs applications
WO2003093317A1 (en)	2002-04-30	2003-11-13	Kyowa Hakko Kogyo Co., Ltd.	Antibody to human insulin-like growth factor
EP2316921B1 (en)	2002-05-24	2014-05-14	Merck Sharp & Dohme Corp.	Neutralizing human anti-IGFR antibody
GB0212303D0 (en)	2002-05-28	2002-07-10	Isis Innovation	Molecular targetting of IGF-1 receptor
US7538195B2 (en)	2002-06-14	2009-05-26	Immunogen Inc.	Anti-IGF-I receptor antibody
EP1596885A2 (en)	2003-02-13	2005-11-23	Pfizer Products Inc.	Uses of anti-insulin-like growth factor i receptor antibodies
CA2518980A1 (en)	2003-03-14	2004-09-30	Pharmacia Corporation	Antibodies to igf-i receptor for the treatment of cancers
US7378503B2 (en)	2003-04-02	2008-05-27	Hoffmann-La Roche Inc.	Antibodies against insulin-like growth factor 1 receptor and uses thereof
JP4638870B2 (ja) *	2003-08-13	2011-02-23	ファイザー・プロダクツ・インク	修飾ヒトｉｇｆ−１ｒ抗体

2004
- 2004-08-03 JP JP2006523070A patent/JP4638870B2/ja not_active Expired - Fee Related
- 2004-08-03 MX MXPA06001634A patent/MXPA06001634A/es unknown
- 2004-08-03 AP AP2006003510A patent/AP2006003510A0/xx unknown
- 2004-08-03 CN CN2004800230991A patent/CN1835975B/zh not_active Expired - Fee Related
- 2004-08-03 DE DE602004029581T patent/DE602004029581D1/de not_active Expired - Lifetime
- 2004-08-03 ES ES04744197T patent/ES2351395T3/es not_active Expired - Lifetime
- 2004-08-03 CA CA002535071A patent/CA2535071A1/en not_active Abandoned
- 2004-08-03 AT AT04744197T patent/ATE484525T1/de active
- 2004-08-03 KR KR1020067002957A patent/KR100825156B1/ko not_active Expired - Fee Related
- 2004-08-03 EP EP04744197A patent/EP1656391B1/en not_active Expired - Lifetime
- 2004-08-03 BR BRPI0413466-4A patent/BRPI0413466A/pt not_active IP Right Cessation
- 2004-08-03 AU AU2004265152A patent/AU2004265152A1/en not_active Abandoned
- 2004-08-03 RS YUP-2006/0099A patent/RS20060099A/sr unknown
- 2004-08-03 PT PT04744197T patent/PT1656391E/pt unknown
- 2004-08-03 UA UAA200601349A patent/UA85058C2/ru unknown
- 2004-08-03 DK DK04744197.7T patent/DK1656391T3/da active
- 2004-08-03 PL PL04744197T patent/PL1656391T3/pl unknown
- 2004-08-03 OA OA1200600046A patent/OA13234A/en unknown
- 2004-08-03 WO PCT/IB2004/002555 patent/WO2005016967A2/en not_active Ceased
- 2004-08-03 EA EA200600234A patent/EA200600234A1/ru unknown
- 2004-08-09 PE PE2004000773A patent/PE20050339A1/es not_active Application Discontinuation
- 2004-08-10 CL CL200402035A patent/CL2004002035A1/es unknown
- 2004-08-11 AR ARP040102870A patent/AR045247A1/es active IP Right Grant
- 2004-08-11 UY UY28464A patent/UY28464A1/es not_active Application Discontinuation
- 2004-08-12 PA PA20048608801A patent/PA8608801A1/es unknown
- 2004-08-12 TW TW093124269A patent/TWI294915B/zh not_active IP Right Cessation
- 2004-08-12 GT GT200400158A patent/GT200400158A/es unknown
- 2004-08-12 NL NL1026829A patent/NL1026829C2/nl not_active IP Right Cessation
- 2004-08-12 US US10/917,073 patent/US7371378B2/en not_active Expired - Fee Related
2006
- 2006-01-19 IL IL173273A patent/IL173273A/en not_active IP Right Cessation
- 2006-01-26 IS IS8266A patent/IS8266A/is unknown
- 2006-02-02 NO NO20060542A patent/NO20060542L/no not_active Application Discontinuation
- 2006-02-10 EC EC2006006359A patent/ECSP066359A/es unknown
- 2006-02-10 ZA ZA200601231A patent/ZA200601231B/en unknown
- 2006-02-13 TN TNP2006000050A patent/TNSN06050A1/fr unknown
- 2006-02-13 CR CR8233A patent/CR8233A/es not_active Application Discontinuation
- 2006-02-13 MA MA28790A patent/MA27988A1/fr unknown
2008
- 2008-03-03 US US12/041,341 patent/US7575746B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US7371378B2 (en)	2008-05-13
EP1656391B1 (en)	2010-10-13
ES2351395T3 (es)	2011-02-04
AP2006003510A0 (en)	2006-02-28
US7575746B2 (en)	2009-08-18
AR045247A1 (es)	2005-10-19
TWI294915B (en)	2008-03-21
CR8233A (es)	2007-01-18
NO20060542L (no)	2006-05-03
OA13234A (en)	2006-12-13
PT1656391E (pt)	2010-12-06
NL1026829C2 (nl)	2005-07-05
JP4638870B2 (ja)	2011-02-23
MXPA06001634A (es)	2006-04-28
CL2004002035A1 (es)	2005-06-03
UY28464A1 (es)	2005-03-31
GT200400158A (es)	2005-07-22
AU2004265152A1 (en)	2005-02-24
WO2005016967A3 (en)	2005-04-14
ZA200601231B (en)	2007-05-30
ECSP066359A (es)	2006-10-31
US20080181891A1 (en)	2008-07-31
WO2005016967A2 (en)	2005-02-24
PA8608801A1 (es)	2005-03-03
CA2535071A1 (en)	2005-02-24
RS20060099A (sr)	2008-08-07
JP2007527705A (ja)	2007-10-04
CN1835975A (zh)	2006-09-20
US20050069539A1 (en)	2005-03-31
UA85058C2 (ru)	2008-12-25
EA200600234A1 (ru)	2006-08-25
KR100825156B1 (ko)	2008-04-24
BRPI0413466A (pt)	2006-10-17
KR20060035796A (ko)	2006-04-26
ATE484525T1 (de)	2010-10-15
NL1026829A1 (nl)	2005-02-15
MA27988A1 (fr)	2006-07-03
IL173273A0 (en)	2006-06-11
TNSN06050A1 (fr)	2007-10-03
DE602004029581D1 (de)	2010-11-25
PE20050339A1 (es)	2005-05-17
DK1656391T3 (da)	2011-01-03
EP1656391A2 (en)	2006-05-17
TW200516145A (en)	2005-05-16
PL1656391T3 (pl)	2011-03-31
CN1835975B (zh)	2012-11-21
IL173273A (en)	2011-10-31

Publication	Publication Date	Title
IS8266A (is)	2006-01-26	Breytt mennsk IGF-1R mótefni
DE602004026768D1 (de)	2010-06-02	Therapeutische anti-igfr1-antikörper-kombinationen
DK1599504T3 (da)	2015-03-09	Modificeret antistof
NO20044347L (no)	2004-12-13	Anti-alfavbeta6-antistoff
DE602004022855D1 (de)	2009-10-08	Interleukin-10-antikörper
NO20071430L (no)	2007-05-15	Anti-OX4OL antistoffer
CY2016035I2 (el)	2017-09-13	Θεραπευτικη χρηση αντισωματων anti-cs1
PL2177537T3 (pl)	2012-06-29	Przeciwciała przeciw MadCAM
NO2016001I2 (no)	2016-01-26	Trastuzumab emtansin
ATE549033T1 (de)	2012-03-15	Therapeutischer menschlicher monoklonaler anti-il-1r1-antikörper
DE502004003292D1 (de)	2007-05-03	Flugzeug
EP1607081A4 (en)	2009-05-13	COSMETIC PREPARATION
ITMI20041123A1 (it)	2004-09-03	Fissaggio
DE502004011106D1 (de)	2010-06-10	6-arylmethyl-substituierte pyrazolopyrimidine
DE502004012209D1 (de)	2011-03-31	Einparkhilfe
DK1809660T3 (da)	2014-10-20	Thymus-specifikt protein
PT1678290T (pt)	2017-10-16	Resumo
EP1646401A4 (en)	2007-07-18	SPECIFIC HUMAN ANTIBODIES
DE502004009935D1 (de)	2009-10-01	Substituierte dihydrochinazoline ii
DE602004023341D1 (de)	2009-11-12	Chronograph
NO20053512D0 (no)	2005-07-18	IL-8-liknende proteiner
FR2853701B1 (fr)	2006-03-03	Electrovanne
SI1656391T1 (sl)	2010-12-31	Modificirana humana IGF-1R protitelesa
DK1494693T3 (da)	2011-01-17	Cripto-specifikke antistoffer
NO20052608D0 (no)	2005-05-31	Midkinlignende protein